Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, John M. Pagel et al.|The Lancet|2021Cited by 456
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37